Navigation Links
Fat droplet nanoparticle delivers tumor suppressor gene to tumor and metastatic cells
Date:4/20/2009

Dr. Esther Chang describes the most recent developments in human trials of the first systemic, non-viral, tumor-targeted, nanoparticle method designed to restore normal gene function to tumor cells while completely bypassing normal tissue April 21 at an American Association of Anatomists (AAA) scientific session at Experimental Biology 2009 in New Orleans.

Dr. Chang, a molecular oncologist, and her colleagues at Georgetown University Medical Center's Lombardi Cancer Center, have developed a nanoparticle about one thousandth smaller than a printed period -- that can travel through the blood stream. "Decorated" with a tumor-targeting antibody, the nanoparticle is able to locate primary and hidden metastatic tumor cells and deliver its payload: a fully functioning copy of the P53 tumor suppressor gene.

Normal cells have two copies of the functioning P53 gene. The protein produced by the P53 gene is activated to either coordinate the repair process in cells or induce cell suicide. Loss of normal p53 function results in malignant cell growth and has been linked to resistance to radiotherapy and chemotherapy in a number of cancers.

In earlier work using animal models, Dr. Chang's group delivered functional p53 genes to tumor cells and tumor metastases in 16 different types of cancer, including prostate, pancreatic, melanoma, breast cancer and head and neck cancer. The presence of the replacement genes dramatically improved the efficacy of conventional cancer therapy. That suggests that use of the P53 delivery system eventually would allow physicians to use a lower dose of therapies, achieving the same or enhanced therapeutic results but sharply diminishing the side effects so troublesome in many treatments.

Dr. Chang's nanoparticle delivery system is designed to reduce side effects in another way as well. When the job of reinstating a normal P53 suppressor gene is done, the nanoparticle essentially a little fat droplet wrapped around the gene simply melts away, unlike non-biodegradable delivery systems.

Clinical trials are now underway at the Mary Crowley Medical Research Center, affiliated with Baylor University at Dallas, under the direction of clinical trial principal investigator Dr. John Nemunaitis. The trial already has enrolled six patients with various cancers and anticipates a total of 14. Early results are promising, says Dr. Chang. In addition to evaluating the safety issues for which phase 1 trials are designed, investigators are seeing anti-tumor efficacy. Dr. Chang says she is hopeful that the gene therapy will become a first line treatment that will significantly reduce the probability of recurrent tumors.


'/>"/>

Contact: Sylvia Wrobel
ebpress@gmail.com
770-722-0155
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology technology :

1. RainDance Technologies to Present Sequence Enrichment Using Droplet-Based Microfluidics Workshop at ASHG 2008
2. RainDance Technologies to Present Workshop on Sequence Enrichment Using Innovative Microdroplet-Based Solutions at ASHG 2008
3. Biology in Pico-Liter Droplets is Focus of Presentation at LabAutomation 2009
4. Anthrax vaccine produces immunity with nanoparticles, not needles
5. New nanoparticle vaccine is more effective but less expensive
6. Anthrax vaccine produces immunity with nanoparticles, not needles
7. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
8. DNA technique yields 3-D crystalline organization of nanoparticles
9. Strengthening fluids with nanoparticles
10. All done with mirrors: NIST microscope tracks nanoparticles in 3-D
11. Hydrogen storage in nanoparticles works
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic ... one eye at a time. So which eye do you rinse first if a dangerous ... have Plum Duo Eye Wash with its unique dual eye piece. , “Whether ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
Breaking Biology Technology:
(Date:7/20/2017)... July 20, 2017 Delta (NYSE: DAL ) customers ... Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft ... Delta,s biometric boarding pass ... is now integrated into the boarding process to allow eligible Delta ...
(Date:6/23/2017)... ARMONK, N.Y. and ITHACA, N.Y. ... IBM ) and Cornell University, a leader in dairy ... combined with bioinformatics designed to help reduce the chances ... breaches. With the onset of this dairy project, Cornell ... the Consortium for Sequencing the Food Supply Chain, a ...
(Date:5/23/2017)... 2017  Hunova, the first robotic gym for the rehabilitation and functional ... in Genoa, Italy . The first 30 robots will ... USA . The technology was developed and patented at ... IIT spin-off Movendo Technology thanks to a 10 million euro investment from ... click: ...
Breaking Biology News(10 mins):